

# **Product** Data Sheet

# Berberine ursodeoxycholate

Cat. No.:HY-147246CAS No.:1868138-66-2Molecular Formula: $C_{44}H_{57}NO_8$ Molecular Weight:727.93Target:Others

HO H H H H

Storage: 4°C, sealed storage, away from moisture and light

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture

and light)

Others

### **SOLVENT & SOLUBILITY**

In Vitro

Pathway:

DMSO: 5 mg/mL (6.87 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.3738 mL	6.8688 mL	13.7376 mL
	5 mM	0.2748 mL	1.3738 mL	2.7475 mL
	10 mM			

Please refer to the solubility information to select the appropriate solvent.

### **BIOLOGICAL ACTIVITY**

**Description** Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent

hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of

hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes<sup>[1][2]</sup>.

In Vivo Berberine ursodeoxycholate shows significant reductions in HbA1c (hemoglobin A1c) levels, mean HbA1c levels decreases

by 0.6%<sup>[1]</sup>.

Berberine ursodeoxycholate is ingested in the form of a salt and it is thought that the salt promptly dissociates within the gastrointestinal tract and that Berberine and Ursodeoxycholic acid are differentially absorbed [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

[1]. Harrison SA, et al. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nat Commun. 2021 Sep 17;12(1):5503.

[2]. Di Bisceglie AM, et al. Phai 2020 Nov 12;19(1):239.	rmacokinetics and pharmac	odynamics of HTD1801 (berberine	e ursodeoxycholate, BUDCA) in patients	with hyperlipidemia. Lipids Health Dis.
Caution: Product has not been fully validated for medical applications. For research use only.				
	Tel: 609-228-6898 Address:	Fax: 609-228-5909 1 Deer Park Dr, Suite Q, Monm	E-mail: tech@MedChemExpre	ess.com
		, .		

Page 2 of 2 www.MedChemExpress.com